Paratek Pharma

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP.

US Well Services

Here's what you need to know about trading penny stocks on June 21st The post What to Know About Buying Penny Stocks on June 22nd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 22nd

-- Phase 2b Study in MAB Pulmonary Infections Ongoing and Enrolling as Planned

Paratek Pharmaceuticals' NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Evan Loh, M.D., chief executive officer, will participate in a fireside chat June 9 from 3:30 to 3:55 p.m. Eastern Time at the Jefferies Healthcare Conference in New York City.

Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Evan Loh, M.D., chief executive officer, will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference. The conference will be held in-person and virtually from May 23-26, 2022, with in-person participation held at the Fontainebleau Miami Beach Hotel in Miami Beach, Florida.

Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Evan Loh - CEO Sarah Higgins - Vice President Finance Controller Adam Woodrow - President and Chief Commercial Officer Randy Brenner - Chief Development and Regulatory Officer Conference Call Participants Suji Jeong - Jefferies Robert Hazlett - BTIG Ed Arce - H.C. Wainwright Operator Good afternoon.

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2022 Results - Earnings Call Transcript

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021

Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million

BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at 4:30 p.m. ET to report its financial results for the first quarter of 2022.

Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2021 Results - Earnings Call Transcript

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $106.1 Million Comprised of $68.2 Million from the Core Commercial Business, a 76% increase over Prior Year, and $37.9 Million from the Initial Procurement of NUZYRA under the BARDA Bioshield Contract

Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million

BOSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, March 14 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2021.

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022

A reader contacted me about a company in his area - Louisiana-Pacific, or "LP", a business that's heavily invested in the timber and building materials area. The company pioneered OSB panels in North America and today is the world's largest producer of OSB and engineered wood building products.

Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company

Paratek earns $6 million milestone payment from Zai Lab Paratek earns $6 million milestone payment from Zai Lab

China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2021 Results - Earnings Call Transcript

Paratek (PRTK) delivered earnings and revenue surprises of 22.92% and 6.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.4 Million from the Core Commercial Business a lone , a 30% Increase over Prior Quarter

Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, Nov. 8, 2021 at 4:30 p.m. EST to provide a corporate update and report its financial results for the third quarter ended Sept. 30, 2021. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial: 855-327-6837 and international investors should dial: 631-891-4304. The conference ID is 10017186. Investors can also access the call at: https://viavid.webcasts.com/starthere.jsp?ei=1509402&tp_key=f032c5b8ec. About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.  The company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights. Paratek is also conducting a Phase 2b Study in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex with NUZYRA. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.  Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world. In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA), now valued at up to approximately $304 million, to support the development and U.S.-based manufacturing of NUZYRA for pulmonary anthrax. For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter. About NUZYRA® NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains including Y. pestis (plague), and bioterrorism pathogens such as B. anthracis (anthrax). Please see full Prescribing Information for NUZYRA at www.NUZYRA.com . Forward Looking Statements This press release contains forward-looking statements including statements related to our overall strategy, products, prospects, potential and NTM addressable market. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2020 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

Paratek Pharmaceuticals to Report Third Quarter 2021 Financial Results on Nov. 8, 2021

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Paratek Pharmaceuticals (PRTK) Q3 Earnings Expected to Decline

-- Potential $1 Billion Addressable Market Opportunity in the United States -- Potential $1 Billion Addressable Market Opportunity in the United States

Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)

Acurx Pharmaceuticals LLC

Cidara Therapeutics

Iterum Therapeutics Plc

Melinta Therapeutics

Nabriva Therapeutics

SCYNEXIS

Summit Therapeutics

WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will present data from their clinical and research programs at IDWeek 2021 taking place virtually from September 29-October 3, 2021.

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

The Biomedical Advanced Research and Development Authority (BARDA) has awarded an option under Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) Project BioShield contract.  Related Link:   Paratek's Antibiotic Gets FDA Orphan Drug Tag For Lung Infection.

Paratek Secures BARDA Funding To Develop Nuzyra Antibiotic For Pulmonary Anthrax

-- Additional ~$19M Funding for Expanded Anthrax PEP Development Program

Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

Key highlights include real-world health outcomes data for pneumonia and skin infections, data on in vitro activity against B. anthracis, and real-world experience for nontuberculous mycobacterial infections Key highlights include real-world health outcomes data for pneumonia and skin infections, data on in vitro activity against B. anthracis, and real-world experience for nontuberculous mycobacterial infections

Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2021

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Randy Brenner, Chief Development and Regulatory Officer, will present at the H.C. Wainwright 23rd Annual Global Investment (Virtual) Conference. The on-demand presentation will be available on September 13 at 7:00 a.m. ET.

Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference

The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.

Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM

The FDA has granted Orphan Drug Designation to Paratek Pharmaceuticals Inc's (NASDAQ: PRTK), Nuzyra (omadacycline) for infections caused by Nontuberculous Mycobacteria (NTM).  The orphan drug designation includes NTM pulmonary disease caused by Mycobacterium abscessus complex (MABc), currently in an ongoing Phase 2b study initiated by Paratek.

News for Paratek Pharma Stock (PRTK)